Re:81 Rationale, Feasibility and Acceptability of Ketogenic Diet for Cancer Treatment - 2017년 review 한국논문

[문형철]

beyond reason

Rationale, Feasibility and Acceptability of Ketogenic Diet for Cancer Treatment

Hae-Yun Chung and Yoo Kyoung Park

Additional article information

Abstract

Ketogenic diet has been used for more than 80 years as a successful dietary regimen for epilepsy. Recently, dietary modulation by carbohydrate depletion via ketogenic diet has been suggested as an important therapeutic strategy to selectively kill cancer cells and as adjuvant therapy for cancer treatment. However, some researchers insist ketogenic diet to be highly undesirable as ketogenic diet may trigger and/or exacerbate cachexia development and usually result in significant weight loss. 

This review revisits the meaning of physiological ketosis in the light of this evidence and considers possibility of the use of ketogenic diet for oncology patients. Article search was performed from 1985 through 2017 and finally 10 articles were analyzed. The review focused on the results of human trials for cancer patients and checked the feasibility of using ketogenic diet for cancer patients as adjuvant therapy. The main outcomes showed improvement of body weight changes, anthropometric changes, serum blood profiles, and reduction in novel marker for tumor progression, TKTL1, and increase of ketone body. Lactate concentration was reduced, and no significant changes were reported in the measurements of quality of life. 

Ketogenic diet may be efficacious in certain cancer subtypes whose outcomes appear to correlate with metabolic status, but the results are not yet supportive and inconsistent. Therefore, it warrants further studies.

Keywords: Ketogenic diet, Neoplasms, High-fat diet, Ketosis

참고) TKTL1

INTRODUCTION

Diet and exercise interventions in cancer patients may be of benefit for ameliorating adverse events during cancer treatment and may increase overall survival.1–3 Metabolic processes in cancer are complex and highly regulated, and there is increasing evidence that dietary modulation can be efficacious in managing cancer, i.e., diet rich in fat and protein4 or calorie restriction.5,6Calorie restriction has been shown to reduce the pro-growth signaling, partially achieved by temporarily reducing glucose and circulating insulin-like growth factor 1, which is highly associated with aging and cancer.7 Also, manipulation of the molecular pathways using calorie restriction has been shown to render cancer cells susceptible to standard cytotoxic treatment with radiation and chemotherapy especially strong for breast cancer. However, considering the high drop-out rate (25%), this indicates that adherence to this low-calorie diet requires high commitment to the study participants.

Ketogenic diet is designed specifically to result in ketosis and is emerging as a metabolic therapy for treating cancer. The mechanism can be explained by inducing shortage of glucose and/or lactate for tumor cells to survive. Vander Heiden et al.8 observed that tumors take up enormous amounts of glucose compared to the surrounding tissue and eventually produces lactate through aerobic glycolytic pathway. Therefore, limitation of glucose availability in cancer cell may reduce energy production of cancer cells, and thereby decreasing tumor proliferation.9

The aim of this review is to assess the clinical evidence of ketogenic diet intervention in cancer patients by analyzing human trials.

STUDY SEARCH AND SELECTION

1. Literature search

The eligible literatures were retrieved by searching through databases (PubMed, MEDLINE, and Springer link) from 1985 until July, 2017. Searching keywords included “ketogenic diet” or “ketone”, “cancer” or “tumor”, and “oncology” with no language restriction and was limited to human clinical trials.

2. Inclusion and exclusion criteria

Articles were included under the following criteria: (1) randomized clinical trials with/without control, (2) prospective cohort study, (3) adult population, and (4) ketone diet composition mentioned. The exclusion criteria were as follows: (1) articles with incomplete data, (2) case studies, and (3) reviews. Letters or comments were irrespective.

3. Data extraction

After the completion of article screening, two investigators independently extracted the data from the eligible studies according to the predesigned protocol. The extracted information was summarized by the first author’s name, journal name, publication year, geographical area of study population, mean age of the participants, sample size of the intervention and control groups, detailed dietary regimen and the length of the study, adherence rate, outcome measures, and results of each article, and finally reported side effects.

ELIGIBLE STUDIES

The process of search strategy is presented in Figure 1. The original search yielded a total of 468 citations (limited to clinical trials, human studies, and years from 1985–2017). First, there were 63 articles after removing the duplicates. Then, 47 articles were excluded because of obvious irrelevance after screening the title and abstract. Six among the remained 16 articles were removed after full-text review: 2 for case studies; 4 without available data. Finally, 10 articles were included in this review. The recommendation of the Cochrane Effective Practice and Organization of Care Review systematic review and meta-analyses, randomized controlled studies, and non-randomized controlled studies were included.10

Figure 1

Flowchart of study search and selection.

SUMMARY OF THE STUDY OUTCOMES OF ELIGIBLE ARTICLES

The detailed information of ketone diets from the selected articles are summarized in Table 1.11–20

Table 1

Clinical trials (including prospective cohort study) using KD in cancer patients

A total of 214 subjects were included in the review. Most of the studies were intervention trials except for one prospective cohort study. The mean age of the studies was mostly from late fifties to early seventies. Eight out of ten articles were submitted from European countries (Germany and Italy) and only two were from USA. The duration of experimental intervention ranged from 5 days to 2 years and the outcome measures were mainly focused on the body weight and composition and blood profile. One article measured quality of life (QOL). The adherence rate in 5 studies were 100%, and the rest were from 31% to 85%. Reported side effects in the studies were relatively minor and included only few reported constipation, leg cramps, diarrhea, etc. Subjects maintained on ketogenic diet for a relatively short period (2 weeks in the study by Rossi-Fanelli et al.,12; 1 week in the study by Fearon et al.,11; 5 days in the study by Schroeder et al.16) did not show any significant changes of the markers, such as body weight or blood profile except for decrease in lactate concentration in the tumor tissues. Meanwhile, when subjects were maintained for a longer period, such as 8 weeks, ketogenic diet (normal meal + fat-enriched liquid diet) successfully showed increased energy intake and body weight of the subjects.13 Ketogenic diet in this study was used for only malnourished gastro-intestinal cancer patient with metastases, suggesting the possibility of application in specific cancer patients. Eval‎uation on anticancer biomarkers was not measured in most of the articles except for study by Jansen and Walach18 who found that TKTL1, a novel marker associated with tumor progression, was reduced by a 2-year ketogenic diet.

Notably, the results from Fine et al.,15 Rieger et al.,17 and Klement and Sweeney19 showed that ketone diet increased significant weight loss. These results showed that unlike the consistent ketogenic effects on epilepsy patients, ketogenic effects on cancer patients were not consistent in this review.

KETOGENIC DIET AS A CANCER THERAPEUTIC STRATEGY

Recently, ketogenic diet has been newly emerged as a cancer therapy in both animal models and humans. Some of the preclinical studies have shown the effect of ketogenic diet to reduce tumor growth and improve survival in animal models of malignant glioma,21–23 prostate cancer,24–26 colon cancer,27 and gastrointestinal cancer.28 Low calorie diet, such as fasting inducing a state of ketosis, has been shown to enhance the responsiveness of cancer cells to chemotherapy in pre-clinical cancer therapy models and to ameliorate some of chemotherapy-induced side effects in normal tissues.29

More recently, numerous case reports were reported. First report was derived from confirmed glioblastoma multiforme treated with standard therapy together with a restricted ketogenic diet, and the response observed in the case suggested the possibility of calorie-restricted ketogenic diet.30 - 토마스 사이프리드 교수 연구

Ketogenic diet has been studied intensively in the European country including Germany. In these studies, the physical condition was successfully improved and tumor shrinkage was observed by ketogenic diet.14 The studies here reviewed lack greatly in the homogeneity of type of cancer, location of cancer, the stages of cancer, and the treatment course of the cancer, and thus the results cannot be generalized. Because ketogenic diet normally results in an increased weight loss, there are continuous concerns to apply this diet for cancer patients. In this review, however, we found that ketogenic diet showed no significant adverse effects. It may be possibly because the subjects were adults, while in children long-term ketogenic diet induces renal damage such as kidney stones.31 Any adverse effects reported in this review were constipation, diarrhea, fatigue, etc. In healthy obese adults with low-carbohydrate ketogenic diet for 6 months, the only adverse effects reported were an increase in the level of low-density lipoprotein cholesterol and some shakiness and uneasiness.32

Studies described in this review assessed the effects of a ketogenic diet in cancer patients. Only ten studies were analyzed and the characteristics and study design, the ketogenic diet regimen, the length of study, cancer type and stage, and site were heterogeneous, thereby contributing to a poor conclusion.

As for ongoing clinical trials, there are currently 62 trials assessing low carbohydrate diets as a potential therapy for a variety of diseases of which 13 trials are assessing ketogenic diet as an adjuvant cancer therapy. Three of the studies are not initiated, but, one study with pancreatic cancer patients was terminated because of the low participation and adherence (Table 2).

Table 2

Ongoing clinical trials from clinicalTrials.gov (https://clinicaltrials.gov) (accessed on 08/04/2017)

CONCLUSION

Our main aim in this review was to assess the feasibility and acceptability of ketogenic diet and to assess the changes of outcome variables, such as body composition, biochemical blood profiles, and QOL. From this review, we found further evidence that ketogenic diet in cancer patients is safe and feasible as an adjuvant therapy. As described above, we could conclude that in order to see any significant progression or improvement by ketogenic diet, at least 3 to 4 weeks of ketogenic diet is required. Additionally, we suggest that not only body composition but also biomarker or measures for tumor size or tumor metabolism assessment is essential. We also conclude that the acceptability for ketone diet may be better in some cancer type (better in glioblastoma than gastric cancer).

In conclusion, ketogenic diet can be safely used to cancer patients if carefully monitored. Most importantly, we have to establish standardized treatment protocol which include the length and regimen for ketogenic diet.

ACKNOWLEDGMENTS

This work was supported by the Korea Institute of Planning and Eval‎uation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through the High Value-added Food Technology Development Program, funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) (316055-3).

Footnotes

CONFLICTS OF INTEREST

No potential conflicts of interest were disclosed.

Article information

J Cancer Prev. 2017 Sep; 22(3): 127–134. 

Published online 2017 Sep 30. doi: 10.15430/JCP.2017.22.3.127

PMCID: PMC5624453

PMID: 29018777

Hae-Yun Chung1 and  Yoo Kyoung Park2

1Department of Food and Nutrition, Soongeui Women’s College, Seoul, Korea

2Department of Medical Nutrition, Graduate School of East-West Medical Science, Kyung Hee University, Yongin, Korea

Correspondence to: Yoo Kyoung Park, Department of Medical Nutrition, Graduate School of East-West Medical Science, Kyung Hee University, 1732 Deogyeong-daero Giheung-gu, Yongin 17104, Korea, Tel: +82-31-201-3816, Fax: +82-31-203-3816, E-mail: rk.ca.uhk@krapy, ORCID: Yoo Kyoung Park, http://orcid.org/0000-0002-8536-0835

Received 2017 Sep 4; Revised 2017 Sep 14; Accepted 2017 Sep 14.

Copyright © 2017 Korean Society of Cancer Prevention

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

This article has been cited by other articles in PMC.

Articles from Journal of Cancer Prevention are provided here courtesy of Korean Society of Cancer Prevention

REFERENCES

1. Demark-Wahnefried W, Morey MC, Sloane R, Snyder DC, Cohen HJ.Promoting healthy lifestyles in older cancer survivors to improve health and preserve function. J Am Geriatr Soc 2009;57 Suppl 2:S262–4.10.1111/j.1532-5415.2009.02507.x [PMC free article] [PubMed] [CrossRef] [Google Scholar]

2. Kushi LH, Kwan ML, Lee MM, Ambrosone CB. Lifestyle factors and survival in women with breast cancer. J Nutr 2007;137: 236S–42S. [PubMed] [Google Scholar]

3. Patterson RE, Cadmus LA, Emond JA, Pierce JP. Physical activity, diet, adiposity and female breast cancer prognosis: a review of the epidemiologic literature. Maturitas 2010;66:5–15.10.1016/j.maturitas.2010.01.004 [PubMed] [CrossRef] [Google Scholar]

4. Imoberdorf R, Rühlin M, Ballmer PE. Cancer and nutrition: a paradigma shift. Laryngorhinootologie 2017;96:514–8. [PubMed] [Google Scholar]

5. Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, et al. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med2017;9:eaai8700.10.1126/scitranslmed.aai8700 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Champ CE, Baserga R, Mishra MV, Jin L, Sotgia F, Lisanti MP, et al. Nutrient restriction and radiation therapy for cancer treatment: when less is more. Oncologist 2013;18:97–103.10.1634/theoncologist.2012-0164 [PMC free article][PubMed] [CrossRef] [Google Scholar]

7. Bonkowski MS, Dominici FP, Arum O, Rocha JS, Al Regaiey KA, Westbrook R, et al. Disruption of growth hormone receptor prevents calorie restriction from improving insulin action and longevity. PLoS One2009;4:e4567.10.1371/journal.pone.0004567 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029–33.10.1126/science.1160809 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Huebner J, Marienfeld S, Abbenhardt C, Ulrich C, Muenstedt K, Micke O, et al. Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice. Anti-cancer Res 2014;34:39–48. [PubMed] [Google Scholar]

10. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. http://handbook.cochrane.org. [updated March 2011].

11. Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr 1988;47:42–8. [PubMed] [Google Scholar]

12. Rossi-Fanelli F, Franchi F, Mulieri M, Cangiano C, Cascino A, Ceci F, et al. Effect of energy substrate manipulation on tumour cell proliferation in parenterally fed cancer patients. Clin Nutr 1991;10:228–32.10.1016/0261-5614(91)90043-C [PubMed] [CrossRef] [Google Scholar]

13. Breitkreutz R, Tesdal K, Jentschura D, Haas O, Leweling H, Holm E. Effects of a high-fat diet on body composition in cancer patients receiving chemotherapy: a randomized controlled study. Wien Klin Wochenschr 2005;117:685–92.10.1007/s00508-005-0455-3 [PubMed] [CrossRef] [Google Scholar]

14. Schmidt M, Pfetzer N, Schwab M, Strauss I, Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab (Lond) 2011;8:54.10.1186/1743-7075-8-54 [PMC free article][PubMed] [CrossRef] [Google Scholar]

15. Fine EJ, Segal-Isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition 2012;28:1028–35.10.1016/j.nut.2012.05.001 [PubMed] [CrossRef] [Google Scholar]

16. Schroeder U, Himpe B, Pries R, Vonthein R, Nitsch S, Wollenberg B. Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer. Nutr Cancer 2013;65:843–9.10.1080/01635581.2013.804579 [PubMed] [CrossRef] [Google Scholar]

17. Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol2014;44:1843–52.10.3892/ijo.2014.2382 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Jansen N, Walach H. The development of tumours under a ketogenic diet in association with the novel tumour marker TKTL1: a case series in general practice. Oncol Lett 2016;11:584–92. [PMC free article] [PubMed] [Google Scholar]

19. Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. BMC Res Notes 2016;9:143.10.1186/s13104-016-1959-9 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Tan-Shalaby JL, Carrick J, Edinger K, Genovese D, Liman AD, Passero VA, et al. Modified Atkins diet in advanced malignancies - final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System. Nutr Metab (Lond) 2016;13:52.10.1186/s12986-016-0113-y [PMC free article][PubMed] [CrossRef] [Google Scholar]

21. Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer2011;11:315.10.1186/1471-2407-11-315 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 2003;89: 1375–82.10.1038/sj.bjc.6601269 [PMC free article][PubMed] [CrossRef] [Google Scholar]

23. Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression‎ patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond)2010;7:74.10.1186/1743-7075-7-74 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate 2008;68:11–9.10.1002/pros.20683 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Masko EM, Thomas JA, 2nd, Antonelli JA, Lloyd JC, Phillips TE, Poulton SH, et al. Low-carbohydrate diets and prostate cancer: how low is “low enough”?Cancer Prev Res (Phila) 2010;3:1124–31.10.1158/1940-6207.CAPR-10-0071 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Mavropoulos JC, Buschemeyer WC, 3rd, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, et al. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila) 2009;2:557–65.10.1158/1940-6207.CAPR-08-0188 [PMC free article][PubMed] [CrossRef] [Google Scholar]

27. Beck SA, Tisdale MJ. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Res 1989;49:3800–4. [PubMed] [Google Scholar]

28. Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer 2008;8:122.10.1186/1471-2407-8-122 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med2012;4:124ra27.10.1126/scitranslmed.3003293 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab (Lond)2010;7:33.10.1186/1743-7075-7-33 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. McNally MA, Pyzik PL, Rubenstein JE, Hamdy RF, Kossoff EH. Empiric use of potassium citrate reduces kidney-stone incidence with the ketogenic diet. Pediatrics 2009;124:e300–4.10.1542/peds.2009-0217 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

32. Yancy WS, Jr, Olsen MK, Guyton JR, Bakst RP, Westman EC. A low-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann Intern Med 2004;140:769–77.10.7326/0003-4819-140-10-200405180-00006 [PubMed] [CrossRef]